Welcome to the e-CCO Library!

P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Simões*1, S. Fernandes1, S. Bernardo1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Tato Marinho1

Created: Friday, 22 February 2019, 9:41 AM
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Guerra Marina, I.(1)*;Bujanda, L.(2,3);Mañosa, M.(3,4);Pérez-Martínez, I.(5);Casanova, M.J.(3,6);de la Peña, L.(7);de Benito, M.(8);Rivero, M.(9);Varela, P.(10);Bernal, L.(3,11);Franco, A.C.(12);Ber, Y.(13);Piqueras, M.(14);Tardillo, C.(15);Ponferrada, Á.(16);Olivares, S.(17);Lucendo, A.J.(18);Gilabert, P.(19);Sierra Ausín, M.(20);Bellart, M.(1);Herrarte, A.(2);Calafat, M.(3,4);de Francisco, R.(5);P. Gisbert, J.(3,6);Guardiola, J.(7);Domènech, E.(3,4);Bermejo, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P386: Methotrexate use in combination with anti-TNFα agents in IBD: A tertiary centre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Waddingham*, A. Nwaogu, E. Michael, L. Whitley, H. Parker, R. Kettle, I. Parisi, E. Seward, S. McCartney, S. Bloom, R. Vega, F. Rahman, S. Mehta

Created: Thursday, 21 February 2019, 9:14 AM
P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
Year: 2022
Source: ECCO'22
Authors: Hubert, A.(1);Bottieau, J.(1);Toubeau, J.F.(1);Franchimont, D.(2,3);Vallée, F.(1);Liefferinckx, C.(2,3);
Created: Friday, 11 February 2022, 3:52 PM
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
Year: 2021
Source: ECCO'21 Virtual
Authors: Mardare, R.(1);Burgess, N.(1);Studart, D.(1);Deb, P.(1);Gasparetto, M.(1);Croft, N.(1);Naik, S.(1);Kadir, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Yarur1, G.J. Mantzaris2, U. Kopylov3, M. Bassel4, N. Brett4, H. Kim5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, B. Bressler12

Created: Thursday, 30 January 2020, 10:12 AM
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
Year: 2021
Source: ECCO'21 Virtual
Authors: Lin, S.(1,2);Bewshea, C.(2);Chanchlani, N.(2);Chee, D.(1,2);Pollok, R.C.(3,4);Kennedy, N.A.(1,2);Ahmad, T.(1,2);Goodhand, J.R.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Sire, R.(1)*;Rispo, A.(1);Caiazzo, A.(1);Testa, A.(1);Nardone, O.M.(1);Guarino, A.D.(1);Olmo, O.(1);Calabrese, G.(1);Fierro, G.(1);Toro, B.(1);Cantisani, N.M.(1);Ferrante, M.(1);La Mantia, A.(1);D'Alessandro, E.(1);Castiglione, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P387: Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Domínguez Sánchez*, G. Pujol Muncunill, S. Pinillos Pison, V. Vila Miravet, J. Martín de Carpi

Created: Friday, 22 February 2019, 9:49 AM
P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Ishikawa*1, M. Takahashi1, K. Okahara1, S. Ito1, K. Haga1, T. Shibuya1, T. Osada2, A. Nagahara1

Created: Friday, 22 February 2019, 9:41 AM
P387: Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.B. Ruiz-Agüello*, A. Maguregui, A. Martínez, D. Nagore

Created: Thursday, 21 February 2019, 9:14 AM
P387: Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program
Year: 2022
Source: ECCO'22
Authors: Komeylian, H.(1);Stewart, M.(1);Currie, B.(2);Phalen-Kelly, K.(2);Heisler, C.G.(2);Jones, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P387: The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Macaluso F.S., Sapienza C., Ventimiglia M., Renna S., Rizzuto G., Orlando R., Affronti M., Orlando E., Cottone M., Orlando A.

Created: Wednesday, 20 February 2019, 10:36 AM
P388 Prediction model to safely CEASE anti-TNF therapy in Crohn’s disease: validation of a predictive diagnostic tool for the cessation of anti-TNF treatment in CD in a Dutch population
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Ten Bokkel Huinink1, D. de Jong2, J. van der Woude1, D. Nieboer3, E. Steyerberg4, F. Wolfhagen5, B. van Tuyl6, R. West7, T. Romkens8, A. Tan9, F. Hoentjen10, W. Mares11, A. Bodelier12, G. Dijkstra13, R. Mallant14, N. de Boer15, J. Reinders16, P. van Boeckel17, G. Tack18, M. Duijvestein15, G. D’Haens2, A. de Vries1

Created: Thursday, 30 January 2020, 10:12 AM
P388: Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Mishkin, D.(1);Marano, C.(2);Simi, A.(2);Lynch, J.(2);Noonan, L.(2);Zhang, H.(2);Sands, B.E.(3);Reinisch, W.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. A. Farraye1, T. Qazi1, P. G. Kotze*2, G. T. Moore3,4, C. Kayhan5, R. Mundayat5, E. Maller5, C. Su5, A. Soonasra5

Created: Friday, 22 February 2019, 9:41 AM
P388: Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic
Year: 2022
Source: ECCO'22
Authors: King, A.(1);Speight, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P388: Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patient
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Shah*, S. Naymagon, B. Cohen, B. Sands, M. Dubinsky

Created: Friday, 22 February 2019, 9:49 AM
P388: Response to IV steroid therapy in acute severe ulcerative colitis (ASUC) is not altered by admission to a tertiary referral centre: The NHS Lothian experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Manship*, R. Grant, F. Jagger, R. Lynch, C. Lees, J. Satsangi, I. Arnott

Created: Thursday, 21 February 2019, 9:14 AM
P388: Risk of relapse in ulcerative colitis patients in clinical remission with combination therapy (anti-TNF and azathioprine) after immunomodulator discontinuation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mihai C., Dranga M., Gavrilescu O., Ungureanu I., Didita A., Chiosa A.M., Savin A., Popa I., Popa R., Jigaranu O., Cijevschi-Prelipcean C.

Created: Wednesday, 20 February 2019, 10:36 AM